ANIXA BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
ANIXA BIOSCIENCES, INC. (ANIX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$2.64 million for the 3-month period ending 2020-04-30, per its 10-Q filed 2020-06-09.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2020-06-09
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-04-30 was -$2.64M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-01-31 was -$2.59M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-10-31 was -$2.09M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-07-31 was -$2.14M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$11.65M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$14.00M.
- ANIXA BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$7.02M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-04-30 | -$2.64M 10-Q · filed 2020-06-09 | -$5.23M 10-Q · filed 2020-06-09 | -$7.32M derived: sum of 3 quarters · filed 2020-06-09 | -$9.46M derived: sum of 4 quarters · filed 2020-06-09 |
| 2020-01-31 | -$2.59M 10-Q · filed 2020-03-09 | -$4.68M derived: sum of 2 quarters · filed 2020-03-09 | -$6.82M derived: sum of 3 quarters · filed 2020-03-09 | -$9.36M derived: sum of 4 quarters · filed 2020-06-09 |
| 2019-10-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09 | -$4.23M derived: sum of 2 quarters · filed 2020-01-09 | -$6.77M derived: sum of 3 quarters · filed 2020-06-09 | -$11.65M 10-K · filed 2020-01-09 |
| 2019-07-31 | -$2.14M 10-Q · filed 2019-09-06 | -$4.68M derived: sum of 2 quarters · filed 2020-06-09 | -$9.56M 10-Q · filed 2019-09-06 | -$14.86M derived: sum of 4 quarters · filed 2020-06-09 |
| 2019-04-30 | -$2.54M 10-Q · filed 2020-06-09 | -$7.42M 10-Q · filed 2020-06-09 | -$12.72M derived: sum of 3 quarters · filed 2020-06-09 | -$18.20M derived: sum of 4 quarters · filed 2020-06-09 |
| 2019-01-31 | -$4.88M 10-Q · filed 2020-03-09 | -$10.18M derived: sum of 2 quarters · filed 2020-03-09 | -$15.66M derived: sum of 3 quarters · filed 2020-03-09 | -$17.04M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-10-31 | -$5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09 | -$10.78M derived: sum of 2 quarters · filed 2020-01-09 | -$12.16M derived: sum of 3 quarters · filed 2020-01-09 | -$14.00M 10-K · filed 2020-01-09 |
| 2018-07-31 | -$5.48M 10-Q · filed 2019-09-06 | -$6.86M derived: sum of 2 quarters · filed 2019-09-06 | -$8.69M 10-Q · filed 2019-09-06 | -$10.48M derived: sum of 4 quarters · filed 2019-09-06 |
| 2018-04-30 | -$1.38M 10-Q · filed 2019-06-12 | -$3.22M 10-Q · filed 2019-06-12 | -$5.00M derived: sum of 3 quarters · filed 2019-06-12 | -$6.80M derived: sum of 4 quarters · filed 2019-06-12 |
| 2018-01-31 | -$1.84M 10-Q · filed 2019-03-13 | -$3.62M derived: sum of 2 quarters · filed 2019-03-13 | -$5.42M derived: sum of 3 quarters · filed 2019-03-13 | -$5.26M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-10-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | -$3.58M derived: sum of 2 quarters · filed 2019-01-11 | -$3.42M derived: sum of 3 quarters · filed 2019-01-11 | -$7.02M 10-K · filed 2019-01-11 |
| 2017-07-31 | -$1.79M 10-Q · filed 2018-09-07 | -$1.63M derived: sum of 2 quarters · filed 2018-09-07 | -$5.23M 10-Q · filed 2018-09-07 | |
| 2017-04-30 | $160.49K 10-Q · filed 2018-06-11 | -$3.44M 10-Q · filed 2018-06-11 | ||
| 2017-01-31 | -$1.59M 10-Q · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |